MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AstraZeneca

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca's 9M and Q3 2025 Financial Results
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca unveils expanded manufacturing facility in Texas
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III ​trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
FLUMIST (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca results: H1 and Q2 2025
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
TAGRISSO® (osimertinib) plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
From AstraZeneca
Via Business Wire
Tickers AZN
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story